SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

GRAIL logo
2 weeks ago

Associate Director, Email/SMS and CRM #4886

GRAIL

Menlo Park, CA (Hybrid)Full time$156K/yr – $207K/yr

Find marketing roles you could actually win

1 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media

Find marketing roles you could actually win

1 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media
1 jobs
GRAIL logo

Associate Director, Email/SMS and CRM #4886

GRAIL

Menlo Park, CA (Hybrid)

$156K/yr - $207K/yrIn-houseFull-timeSenior level12+ years exp.
2 weeks ago
GRAIL logo
GRAIL

Associate Director, Email/SMS and CRM #4886

Menlo Park, CA (Hybrid)

$156K/yr – $207K/yrSenior Level12+ years expFull time

Posted 2 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own email program governance for B2B and healthcare audiences while balancing compliance with aggressive optimization across Pardot, Marketing Cloud, and Paubox.

  • Own transactional and lifecycle email journeys for patient and provider segments.
  • Coordinate with Audience, Sales, and IT to improve deliverability, reporting, and attribution.
  • Lead data-driven testing and lead scoring to lift engagement and conversions while ensuring CAN-SPAM, GDPR, and TCPA compliance.

Job Description

Responsibilities

  • Expertise and ability to administer Pardot, Salesforce Marketing Cloud, and Paubox; provide strategic and tactical support to the Salesforce.com Administrator.
  • Execute all B2B, customer, patient, and provider-based email and SMS campaigns in collaboration with Audience team marketers.
  • Own product-oriented patient and provider transactional email journeys.
  • Demonstrate success across marketing automation platforms, including lead scoring based on audience behaviors; be results-focused.
  • Develop and manage tactical execution plans focused on the customer; drive engagement and meet key objectives.
  • Analyze email program performance metrics and optimize deliverability, opens, click-to-open, CTRs, opt-out rates, and conversions; build weekly/monthly reports.
  • Create and deploy different types of email journeys for Marketing and other business teams (Customer Experience, Sales, Finance, Medical Affairs).
  • Create UTM links following standard naming conventions for tracking and analytics.
  • Project management: planning projects, prioritization, and deadlines.
  • Ensure email templates perform across device types and comply with best practices and GRAIL compliance.

Requirements

  • 12+ years in an email management role serving B2B and B2C audiences using Salesforce tools (Marketing Cloud Account Engagement aka Pardot, Marketing Cloud, NEXT)
  • 5 years of experience managing a team
  • Bachelor’s Degree (Master's preferred)
  • 5 years of experience in healthcare marketing (pharma, med device, life sciences, or provider/health systems)
  • Strong verbal and written communication skills (including storytelling using data)
  • Deep experience in lead scoring based on audience behaviors
  • Keen attention to detail with brand stewardship
  • Strong data analysis skills; experience with A/B testing and KPI-driven improvements
  • Strong understanding of data privacy (CAN-SPAM, GDPR, TCPA)
  • Own all compliance and data governance for Email/SMS activities and platforms
  • Proficiency with basic HTML/CSS editing and email performance tools (e.g., Litmus)
  • Demonstrated ability to collaborate cross-functionally in a fast-paced environment
  • Self-starter who can lead and run projects end-to-end
  • Ability to serve as liaison between internal business and technical teams to satisfy requirements
  • Experience documenting complicated processes and using applications like Veeva for compliance/training

Preferred

  • A range of experience from startups to large brand email experience
  • Experience with an aspirational/emotional business where email content drove revenue and brand adoption
  • Health Cloud experience is nice to have
  • Familiarity with Mac and G-Suite
  • Experience with Salesforce Next
  • Experience with ABM best practices
  • Proficient with Tableau (preferred but not required)
  • Experience with Asana and JIRA (helpful)
  • Global and multi-product experience
  • Experience using AI to drive efficiency

Benefits

  • comprehensive and competitive benefits package
  • flexible time-off or vacation
  • 401(k) retirement plan with employer match
  • medical, dental, and vision coverage
  • mindfulness programs
GRAIL logo

GRAIL

3.2 Glassdoor

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com.Community Guidelines: https://bit.ly/3xigb24

Founded in 2016
Menlo Park, California, USA
www.grail.com
51% recommend to a friend
49% CEO approval

Marketing Team

Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$2.4B
Last Raise
$325M
Post IPO Equity, 5 months ago

Funding History

  • Oct 2025
    Post IPO Equity • $325M
  • Oct 2025
    Post IPO Equity • $110M
  • May 2020
    Series D • $390M

Recent News

Grail sees Q3 sales jump, eyes Q1 for FDA Galleri PMA submission
Nov 13, 2025 • Fierce Biotech
GRAIL Reports Third Quarter 2025 Financial Results
Nov 12, 2025 • PR Newswire
Here's Why Grail Stock Exploded Higher by 55% in October
Nov 6, 2025 • The Motley Fool
GRAIL (GRAL) Is Up 8.2% After Strong SYMPLIFY Data Underscores Galleri’s Early Cancer Detection Potential
Nov 3, 2025 • Yahoo Finance
Why The Story Around GRAIL Is Shifting After Recent Analyst and Clinical Developments
Nov 2, 2025 • Yahoo Finance
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
Oct 31, 2025 • The Cancer Letter
GRAIL to use new study results to seek FDA approval of Galleri MCD test
Oct 24, 2025 • The Cancer Letter
Jim Cramer on GRAIL: “Don’t Call Yourself Early if You’re Buying This One”
Oct 24, 2025 • Yahoo Finance
GRAIL, Inc. (GRAL): A Bull Case Theory
Oct 23, 2025 • Yahoo Finance
Wall Street Wonders if Grail’s Cancer Test Results Are a True Positive
Oct 22, 2025 • Barron's
Wall Street Wonders if Grail’s Cancer Test Results Are a True Positive
Oct 22, 2025 • Barron's
A Fresh Look at GRAIL (GRAL) Valuation Following a Year of Strong Share Price Momentum
Oct 21, 2025 • Yahoo Finance
Grail's CEO Sells 7,200 Shares for nearly $500,000
Oct 21, 2025 • The Motley Fool
Latham Advises GRAIL on Investment and Strategic Collaboration With Samsung Separate PIPE Financing
Oct 21, 2025 • Latham & Watkins
After financial troubles, Grail raises $325M from Hims and others
Oct 21, 2025 • Endpoints News
Cancer early-detection test company Grail raises $325 million
Oct 20, 2025 • The Business Journals
Grail stock soars on positive cancer test results and $325M funding
Oct 20, 2025 • Investing.com
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
Oct 20, 2025 • PR Newswire
ESMO: Grail eyes FDA review with boosted performance data from Galleri cancer blood test
Oct 20, 2025 • Fierce Biotech
Grail To Issue And Sell 4.6 Mln Shares At $70.05/shr In Private Placement; Shares Rise In Pre-market
Oct 20, 2025 • Nasdaq
GRAIL Galleri SYMPLIFY: PPV 84.2% in Symptomatic Patients | GRAL Stock News
Oct 20, 2025 • Stock Titan
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
Oct 20, 2025 • PR Newswire
Grail's DNA blood test improves early cancer detection sevenfold
Oct 20, 2025 • BioWorld MedTech
Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission
Oct 20, 2025 • Patient Care Online
'Holy grail' blood test for more than 50 cancers brings 'exciting' results
Oct 20, 2025 • Medical Xpress
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
Oct 18, 2025 • PR Newswire
Grail Blood Test Found Seven Times More Cancers Than Standard Tests, Data Show
Oct 18, 2025 • Barron's
Grail Blood Test Found Seven Times More Cancers Than Standard Tests, Data Show
Oct 18, 2025 • Barron's
ESMO: Grail's data on cancer blood test firms up
Oct 18, 2025 • pharmaphorum
Grail says new data on multi-cancer screening test show improved performance
Oct 17, 2025 • statnews.com
Samsung entities, Grail to roll out early cancer detection test in Asia
Oct 17, 2025 • Medical Device Network
GRAIL (GRAL) Is Up 21.5% After Samsung Partnership to Expand Galleri Test in Asia – What's Changed
Oct 17, 2025 • Yahoo Finance
GRAIL Stock Analysis: Samsung Partnership Drives Rally, But Fundamentals Warrant Caution
Oct 17, 2025 • Trefis
What’s Happening With GRAIL Stock?
Oct 17, 2025 • Forbes
Samsung invests $110m in US biotech firm Grail for Asia cancer test push
Oct 17, 2025 • The Korea Herald
Samsung to invest $110 mn in Grail to bring early-cancer test to Asia
Oct 17, 2025 • The Korea Economic Daily Global Edition
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia
Oct 17, 2025 • samsung.com
Grail stock surges after Samsung announces $110 million investment By Investing.com
Oct 16, 2025 • Investing.com
Why Grail Stock Soared 14% Higher on Thursday
Oct 16, 2025 • The Motley Fool
Grail Stock Jumps 14% After Samsung Partnership To Launch Galleri Test In Asia
Oct 16, 2025 • Nasdaq
Grail Inc stock hits all-time high at 75.56 USD
Oct 15, 2025 • Investing.com
President Joshua Ofman Sold A Bunch Of Shares In GRAIL
Oct 11, 2025 • simplywall.st
GRAIL (GRAL): Evaluating Valuation After 20% Revenue Growth and Modest Share Price Gains
Oct 7, 2025 • Yahoo Finance
Grail Inc stock hits all-time high of 64.0 USD
Oct 2, 2025 • Investing.com
Why Is GRAIL Stock Rising?
Sep 29, 2025 • StocksToTrade
Will Rising Galleri Adoption Drive Growth For GRAIL Stock?
Sep 26, 2025 • RTTNews
This Cancer Detection Pioneer Is Worth a Look
Sep 26, 2025 • The Motley Fool
GRAIL to Showcase New Data for Galleri Multicancer Early Detection Test at Key Fall Meetings
Sep 24, 2025 • Patient Care Online
GRAIL to present first PATHFINDER 2 results at ESMO Congress
Sep 23, 2025 • Investing.com
GRAIL Gains Momentum Post-IPO Amid Strong Sales, Partnerships, and Executive Share Activity
Sep 20, 2025 • Yahoo Finance
Biotech company ditches Menlo Park for another Bay Area headquarters
Sep 18, 2025 • Seattle TechFlash
Blood Testing Market to Reach USD 249.7 Billion by 2035, Growing at 8.2% CAGR from USD 104.4 Billion in 2024 | TMR
Sep 12, 2025 • EIN Presswire
GRAIL (GRAL) Stock Surges 19% In Last Week
Sep 10, 2025 • Yahoo Finance
GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
Sep 10, 2025 • PR Newswire
GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
Sep 10, 2025 • MarketScreener
GRAIL Earns Relative Strength Rating Upgrade
Sep 8, 2025 • Investor's Business Daily
Alcon and GRAIL: Unlocking Innovation and Efficiency through Strategic Partnerships
Sep 4, 2025 • Veeva
GRAIL: Intriguing Cancer Testing Product Needs More Time And FDA Approval (GRAL)
Aug 31, 2025 • Seeking Alpha
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 29, 2025 • PR Newswire
GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 26, 2025 • PR Newswire
GRAIL, Inc. (NASDAQ:GRAL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.50
Aug 16, 2025 • Yahoo Finance
Earnings call transcript: Grail Inc reports Q2 2025 earnings beat, stock rises
Aug 12, 2025 • Investing.com
Grail reports Q2 EPS ($3.18), consensus ($3.56)
Aug 12, 2025 • thefly.com
GRAIL Reports Second Quarter 2025 Financial Results
Aug 12, 2025 • PR Newswire
Grail Inc options imply 12.6% move in share price post-earnings
Aug 12, 2025 • thefly.com
Transcript : GRAIL, Inc., Q2 2025 Earnings Call, Aug 12, 2025
Aug 12, 2025 • MarketScreener
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024
Aug 11, 2025 • Research and Markets
Galleri Test: Revolutionizing Cancer Screening With One Simple Blood Draw | DataM Intelligence
Aug 11, 2025 • EIN Presswire
🔬 Multi-Cancer Early Detection Market Set to Revolutionize Cancer Diagnosis by 2034 | Driven by Liquid Biopsy Innovations and AI Integration
Aug 6, 2025 • PharmiWeb
Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR | MarketsandMarkets™
Aug 5, 2025 • PR Newswire UK
Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR | MarketsandMarkets™
Aug 5, 2025 • PR Newswire
GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference
Jul 31, 2025 • BioSpace
GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025 • PR Newswire
Cancer Detection Pioneer GRAIL Sets Q2 Earnings Call: Key Details for Healthcare Investors
Jul 29, 2025 • Stock Titan
GRAIL to Announce Second Quarter 2025 Financial Results
Jul 29, 2025 • PR Newswire
Genetic Testing Market to Soar to $54.2B by 2033, Driven by Personalized Medicine and Tech Innovation
Jul 28, 2025 • EIN Presswire
11 Companies Hiring in California
Jul 23, 2025 • BioSpace
Grail’s CFO Freidin sells $311k in common stock
Jul 17, 2025 • Investing.com
Grail Insider Sold Shares Worth $311,440, According to a Recent SEC Filing
Jul 17, 2025 • MarketScreener
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission
Jul 14, 2025 • Yahoo Finance
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance
Jul 9, 2025 • Yahoo Finance
Grail Insider Sold Shares Worth $503,984, According to a Recent SEC Filing
Jul 1, 2025 • MarketScreener
Minimal Residual Disease Testing Market Analysis 2025 – Insights For Long-Term Investment & Planning
Jul 1, 2025 • EIN Presswire
GRAIL, Inc.(NasdaqGS:GRAL) added to Russell 2000 Value Index
Jun 30, 2025 • MarketScreener
GRAIL, Inc.(NasdaqGS:GRAL) added to Russell 2000 Dynamic Index
Jun 30, 2025 • MarketScreener
STAT+: At Aspen Ideas, a life science VC sees cause for long-term optimism despite a rocky market
Jun 30, 2025 • sdbn.org
STAT+: At Aspen Ideas, a life science VC sees cause for long-term optimism despite a rocky market
Jun 30, 2025 • STAT
GRAIL, Inc.(NasdaqGS:GRAL) dropped from Russell Midcap Index
Jun 29, 2025 • MarketScreener
Institutional investors in GRAIL, Inc. (NASDAQ:GRAL) lost 9.3% last week but have reaped the benefits of longer-term growth
Jun 25, 2025 • Yahoo Finance
Grail plans FDA filing for cancer blood test after new trial
Jun 20, 2025 • pharmaphorum
Grail Ups the Ante with Multi-Cancer Early Detection Test
Jun 20, 2025 • Medical Device and Diagnostic industry
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Jun 20, 2025 • Morningstar.com
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Jun 20, 2025 • Canada NewsWire
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Jun 20, 2025 • PR Newswire UK
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Jun 20, 2025 • PR Newswire
Grail reports positive outcomes from registrational study of Galleri test
Jun 19, 2025 • Medical Device Network
Grail reports positive outcomes from registrational study of Galleri test
Jun 19, 2025 • Yahoo Finance
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Jun 19, 2025 • BioSpace
Grail plans to submit updated Galleri blood test for FDA approval next year
Jun 18, 2025 • Fierce Biotech
GRAIL reports positive results from cancer detection test study
Jun 18, 2025 • Investing.com